Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
An announcement from Clene ( (CLNN) ) is now available.
On September 25, 2025, Clene announced new clinical data at the ECTRIMS 2025 meeting, highlighting that their product CNM-Au8 improves brain energy metabolism in multiple sclerosis patients. This announcement could enhance Clene’s positioning in the pharmaceutical industry, potentially impacting stakeholders by showcasing the effectiveness of their treatment in a significant medical condition.
The most recent analyst rating on (CLNN) stock is a Buy with a $31.00 price target. To see the full list of analyst forecasts on Clene stock, see the CLNN Stock Forecast page.
Spark’s Take on CLNN Stock
According to Spark, TipRanks’ AI Analyst, CLNN is a Neutral.
Clene’s overall stock score is primarily impacted by its financial instability, which poses significant risks. However, strong technical momentum and positive corporate events provide some optimism. The poor valuation due to ongoing losses remains a concern.
To see Spark’s full report on CLNN stock, click here.
More about Clene
Average Trading Volume: 83,091
Technical Sentiment Signal: Buy
Current Market Cap: $60.92M
Learn more about CLNN stock on TipRanks’ Stock Analysis page.